Department of Orthopedics, University Medical Center Utrecht, Utrecht, The Netherlands.
Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Cancer. 2018 Apr 15;124(8):1828-1838. doi: 10.1002/cncr.31240. Epub 2018 Feb 6.
The Spine Oncology Study Group Outcomes Questionnaire (SOSGOQ) was developed as the first spine oncology-specific health-related quality of life (HRQOL) measure. This study evaluated the psychometric properties and clinical validity of the SOSGOQ in a diverse cohort of patients with spinal metastases.
An international, multicenter, prospective observational cohort study including patients with spinal metastases who underwent surgery and/or radiotherapy was conducted by the AOSpine Knowledge Forum Tumor. Demographic, tumor, and treatment data were collected. HRQOL was evaluated using the SOSGOQ and Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) at baseline and fixed follow-up times. Construct validity was assessed using multitrait scaling analyses, confirmatory factor analyses, and correlation with the SF-36 and NRS pain score. Test-retest reliability was assessed in a subgroup of patients between 12 weeks after treatment and the retest 4 to 9 days later.
A total of 238 patients were enrolled at 9 centers across North America; 153 of these patients had HRQOL data available at 12 weeks after treatment. Multitrait scaling analyses and confirmatory factor analyses resulted in a refined version of the SOSGOQ with 4 domains and 4 single items. The revised SOSGOQ (SOSGOQ2.0) demonstrated strong correlations with SF-36 and the ability to discriminate between clinically distinct patient groups. Reliability of the SOSGOQ2.0 was demonstrated to be good, with an intraclass correlation coefficient ranging from 0.58 to 0.92 for the different domains.
The SOSGOQ2.0 is a reliable and valid measure with which to evaluate HRQOL in patients with spinal metastases. It is recommended to use the SOSGOQ2.0 together with a generic HRQOL outcome measure to comprehensively assess HRQOL and increase sensitivity and specificity. Cancer 2018;124:1828-38. © 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
脊柱肿瘤研究组结局问卷（SOSGOQ）是作为首个脊柱肿瘤专用健康相关生活质量（HRQOL）量表而开发的。本研究在接受手术和/或放疗的脊柱转移瘤患者的多元化队列中评估了 SOSGOQ 的心理测量学特性和临床有效性。
由 AOSpine 知识论坛肿瘤开展了一项国际性、多中心、前瞻性观察队列研究，纳入了接受手术和/或放疗的脊柱转移瘤患者。收集了人口统计学、肿瘤和治疗数据。在基线和固定随访时间使用 SOSGOQ 和医疗结局研究短式 36 健康调查（SF-36）评估 HRQOL。使用多特质标度分析、验证性因子分析以及与 SF-36 和 NRS 疼痛评分的相关性评估结构效度。在治疗后 12 周和随后 4 至 9 天进行复测的患者亚组中评估测试-重测信度。
共 238 例患者纳入北美 9 家中心，其中 153 例患者在治疗后 12 周时具有 HRQOL 数据。多特质标度分析和验证性因子分析产生了具有 4 个领域和 4 个单项的改良版 SOSGOQ。修订后的 SOSGOQ（SOSGOQ2.0）与 SF-36 相关性强，并能够区分具有临床意义的不同患者群体。SOSGOQ2.0 的可靠性良好，不同领域的组内相关系数为 0.58 至 0.92。
SOSGOQ2.0 是一种可靠和有效的量表，可用于评估脊柱转移瘤患者的 HRQOL。建议将 SOSGOQ2.0 与通用的 HRQOL 结局测量指标一起使用，以全面评估 HRQOL 并提高敏感性和特异性。癌症 2018；124:1828-38。© 2018 美国癌症协会。Wiley Periodicals, Inc. 是此文章的出版者，并对此文享有所有版权。这是在创作共用署名-非商业性使用-禁止演绎 4.0 国际许可协议下授权的，允许在任何媒体上以任何形式使用、分发，只要注明原始作者和来源，并不能用于商业目的。
